Baicheng Pharmaceutical (301096.SZ): Class 2 Improved New Drug Levosulpiride Sustained-release Granules Obtains Drug Registration Certificate

Zhtng Cijng APP News, Baicheng Pharmaceutical (301096.SZ) announced that its wholly-owned subsidiary, Zhejiang Saimo Pharmaceutical Co., Ltd., recently received the drug registration certificate for the sustained-release granules of levetiracetam approved and issued by the National Medical Products Administration. This drug is a category 2.2 improved new drug, suitable for the adjunctive treatment of partial-onset seizures in patients with epilepsy aged 12 and above. Compared to conventional tablets and sustained-release tablets already on the market, sustained-release granules are more suitable for children and patients with difficulty swallowing, improving patient compliance and demonstrating significant clinical advantages.